- Home
- DAWN vs OLMA Comparison
DAWN vs OLMA Comparison
Compare DAWN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAWN | OLMA |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DAWN | OLMA |
|---|---|---|
| Price | $21.47 | $14.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $26.00 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 5.8M | 1.7M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $158,182,000.00 | N/A |
| Revenue This Year | $55.03 | N/A |
| Revenue Next Year | $28.12 | $347.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.60 | N/A |
| 52 Week Low | $5.64 | $2.86 |
| 52 Week High | $21.47 | $36.26 |
Technical Indicators
Market Signals| Indicator | DAWN | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 81.60 | 38.51 |
| Support Level | $10.30 | $13.11 |
| Resistance Level | N/A | $27.38 |
| Average True Range (ATR) | 0.06 | 0.95 |
| MACD | -0.32 | 0.37 |
| Stochastic Oscillator | 89.47 | 52.92 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.